GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseasesOn track to launch a Phase 2a biomark...

Related Keywords

United States ,Jenene Thomas ,Marc Hertz ,Vallon Pharmaceuticals ,Bio Inc ,Twitter ,Exchange Commission ,Nasdaq ,Linkedin ,Allergan ,Chief Executive Officer ,Lupus Nephritis ,Launch Phase ,Report Phase ,Financial Results ,Second Quarter ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Differential Activation ,Hepatic Invariant ,Subsets Plays ,Key Role ,Very Severe Plaque Psoriasis Briefing Document ,Idiopathic Pulmonary Fibrosis ,Natural History ,Med Sci ,Respir Res ,